A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.
A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...
CHENNAI: After a nine-year-old boy from Thirvur in Tiruvallur district died due to Guillain-Barre Syndrome (GBS) — a rare ...
1d
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.
Experts with the Cleveland Clinic say the drug has a lot of potential, especially since it is considered nonaddictive.
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback